Emergent Travel Health, Inc.

MENLO PARK, Calif.--(BUSINESS WIRE)-- ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the appointment of Dean J. Mitchell as chairman of its Board of Directors. Mr. Mitchell is a highly experienced and well-regarded biotechnology and pharmaceutical industry veteran who brings over three decades of experience as a board director and corporate executive to the ReCode board. “We are delighted to have Dean join the board as we continue to advance our respiratory clinical development programs and leverage our novel SORT LNP delivery platform to expand our portfolio,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics. “His proven track record at growing and scaling biopharma companies is a welcome addition to our board that will support the company’s near- and long-term growth.” “I am pleased to join the talented ReCode board at a pivotal time for the company as it continues to achieve significant milestones for its lead clinical programs and expand its research and discovery efforts into gene correction,” said Mr. Mitchell. “I look forward to working with the board and the executive team to advance these novel therapies with the goal of one day providing much-needed treatments for patients living with rare diseases.” Mr. Mitchell currently serves as chairman of the Board of Directors of Praxis Precision Medicines, Inc., an appointment he has held since 2020, and as a board director for Theravance Biopharma, Inc. (since 2014) and Precigen (since 2009). Mr. Mitchell previously served as board chairman of Kinnate Biopharma, Inc. until its sale in 2024 and as board director for ImmunoGen, Inc. until its sale in 2024. He served as executive board chairman for Covis Pharma Holdings until its sale in 2020 and board chairman of PaxVax Corporation until its sale in 2018. Mr. Mitchell previously held the position of president and chief executive officer at Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, at Alpharma, Inc., a publicly traded specialty pharmaceutical company until its acquisition by King Pharmaceuticals, Inc., and at Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused on oncology and acute care, until its acquisition by MGI Pharma Inc. He previously held executive roles at Bristol Myers Squibb and GlaxoSmithKline. Mr. Mitchell earned a B.A. from City University London and a B.Sc. in biology from Coventry University. About ReCode Therapeutics ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues, and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver, and infectious disease indications. ReCode has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a Best Place to Work. For more information, visit and follow us on LinkedIn and Instagram.

Antonio F. Santidrian, PharmD, Ph.D., promoted to Chief Scientific Officer and Amish Patel, Ph.D., promoted to Senior Vice President of Technical Operations Alan Stewart appointed to Board of Directors SAN DIEGO--(BUSINESS WIRE)-- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced two key promotions from the clinical leadership team and the appointment of a new Board Director. Antonio Santidrian, PharmD, Ph.D., previously Senior Vice President, Global Head of Research and Development, has been promoted to Chief Scientific Officer and Amish Patel, Ph.D., has been promoted to Senior Vice President of Technical Operations. In addition, Alan Stewart, a Calidi advisor since 2020, has been appointed to the Board of Directors. Mr. Stewart will replace Dr. Heehyoung Lee as an independent Director and Chair of the Audit Committee. “I am delighted to announce the well-deserved promotions of Drs. Santidrian and Patel, who have been instrumental in the development and manufacturing of our differentiated cell-based delivery platforms,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. “As CSO, Dr. Santidrian will continue to apply his expertise in oncology and leadership in discovery, to expand the potential of our novel technology. In Dr. Patel’s new role, he will continue to innovate and accelerate Calidi’s leading technical and manufacturing capabilities to drive the clinical advancement of our assets. Alan Stewart’s previous role serving as an advisor to Calidi, as well as his strong financial and capital markets background, will be invaluable to us as a newly public company. Lastly, I would like to thank Dr. Lee, one of Calidi’s earliest investors, for her support and guidance over the last three years and wish her well in her future endeavors.” Antonio F. Santidrian, PharmD, Ph.D., previously served as Senior Vice President, Global Head of Research and Development at Calidi since September 2021. Dr. Santidrian has over 22 years of experience in anti-cancer translational research and drug development, and as Chief Scientific Officer will lead research and development activities to fully leverage the potential of Calidi’s Pipeline and first-in-class allogeneic stem cell-based delivery platforms to provide a new generation of targeted and universal cancer immunotherapies. Dr. Santidrian is co-inventor of Calidi’s Supernova platform, a universal cell-based delivery platform designed to protect, amplify, and potentiate oncolytic viruses to enhance efficacy and improve patient safety. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute for several small molecule and biologic drugs treating metastatic breast cancer. Dr. Santidrian worked closely on the translational cancer studies for the development of ACADRA to treat Chronic lymphocytic leukemia (CLL) at the University of Barcelona. Dr. Santidrian is the recipient of a fellowship from the Ministry of Science and Education (Spain), Susan G. Komen Breast cancer foundation, and the August Pi I Sunyer Foundation. Dr. Santidrian received a degree in Pharmacy (equivalent to the PharmD program) from the University of Barcelona in 2001 and a Ph.D. in biomedicine, specializing in anti-cancer therapies, in 2006 from the University of Barcelona in Barcelona, Spain. Amish Patel, Ph.D., previously served as Vice President of Technical Operations since joining Calidi in August 2022. Dr. Patel has over 19 years of global biopharma and biotech leadership experience, providing strategic guidance throughout the entire biologic product life cycle. Dr. Patel will be responsible for overseeing global manufacturing, quality, and supply chain to produce clinical and commercial therapies utilizing Calidi’s innovative cell-based delivery of oncolytic viruses. Over the course of his career, he has led the development of over 15 INDs, two commercial product approvals, and numerous PAS submissions. He was most recently the Senior Director of Product Development at Emergent BioSolutions (formerly PaxVax, Inc., prior to acquisition), where he successfully built and directed cross-functional teams working on numerous technology platforms. Prior to Emergent, Dr. Patel led the technical development of oral insulin delivery technology at Ansun Biopharma and cell transplantation therapy for patients with diabetes at MicroIslet Inc. Dr. Patel also serves as a member of the Technical Activities Committee of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) part of Manufacturing USA® which is funded through U.S. Department of Commerce with significant additional support from its members. He also serves ad hoc on a scientific review panel at National Institutes of Health. Dr. Patel received his Ph.D. in Engineering/Nanotechnology and M.S. in Chemical Engineering from Louisiana Tech University specializing in using nanotechnology tools for enzyme and DNA encapsulation and delivery funded by a NASA grant. He has his Bachelor of Engineering in Chemical from Poona University, India. Alan Stewart has worked as an advisor to Calidi since 2020. Currently, he serves as the Chief Financial Officer at SoundThinking (formerly known as ShotSpotter Inc.). Prior to joining SoundThinking, he served as Managing Director of RA Capital Advisors, LLC, a private investment bank specializing in mergers and acquisitions, private financings, and restructurings. In addition to his experience in banking and private finance, Alan served as the CEO of FIT Advisors, LLC, a boutique consulting firm that offers temporary CFO services and worked with clients from start-up ventures to large private companies. He currently serves as a Director at Round Feather Inc. and Ravenswood Solutions Inc. and was awarded CFO of the Year by the San Diego Business Journal in both 2007 and 2013. In 2021, Mr. Stewart was one of the Finalists (one of three) as CFO of the Year for Northern California, including San Francisco and Silicon Valley. In 2023, he was selected as one of San Francisco’s Top 25 CFOs and one of the Top 10 Inspiring CFOs (C-Level Focus Magazine). Prior to his business career, Mr. Stewart served over ten years as a submarine nuclear engineer in the United States Navy. He received his B.S. in Oceanography, with distinction, from the U.S. Naval Academy and his M.B.A. from the Harvard Business School. About Calidi Biotherapeutics: Calidi Biotherapeutics (NYSE: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy delivering a payload to target and kill tumor cells. Calidi Biotherapeutics is advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit . Forward-Looking Statements This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Calidi will be those that it has anticipated. Any forward-looking statements involve a number of risks, uncertainties (some of which are beyond Calidi’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Form S-1 registration statement filed with the SEC and dated October 6, 2023

双抗已有24亿美元重磅品种，近年将迎来上市爆发期，218款在研药物中，大部分双抗产品仍然处于Ⅰ期临床试验，伴随研发逐步推进，未来的3-5年将有望迎来双抗药物上市井喷。从适应症布局看，超过 80% 的管线集中在肿瘤领域，其中实体赛道最为热门。由于我国起步较晚，国产自研产品主要集中在临床前，目前已有近 80 款双抗药物处于申报临床及以上的研发状态，超过44家国内药企参与布局。双抗作为第二代抗体药物有望填补治疗空白。从作用机制来看，双抗大致可以被分为四个类型，分别为细胞桥接、双靶点阻断、免疫细胞激活、促蛋白复合体生成机制。根据目前公布的临床数据，双抗已展现出相比单抗联用疗法、CAR-T和小分子药更好的疗效，甚至在这些现有疗法治疗失败或产生耐药的患者中也出现显著有效应答。 我们认为，伴随技术的持续进步以及临床的不断推进，双抗有望填补甚至取代现有疗法在部分适应症中的应用，成为未来重要的临床治疗选择之一。康日百奥生物科技（苏州）有限公司，是专业的生物药CDMO企业，联合医药行业头部媒体E药经理人，于2023年6月20日重磅推出《探“奥”抗体新工艺直播课》届时，邀请到逻晟生物董事长 董欣博士带来精彩报告《单抗&双抗&ADC，如何从研发视角跳出同质化》。康日百奥技术运营副总经理 朱一翔博士带来报告《将理想变为现实—双抗及复杂重组蛋白工艺开发关键要点和策略》欢迎行业小伙伴前来交流！01活动形式微解药线上直播观看直播02直播时间2023年6月20日 19:30-21:1003直播日程19:30-19:35主持人开场19:35-20:20报告：单抗&双抗&ADC，如何从研发视角跳出同质化嘉宾：董欣 逻晟生物董事长20:20-20:25Q&A20:25-21:05报告：将理想变为现实——双抗及复杂重组蛋白工艺开发关键要点和策略嘉宾：朱一翔 康日百奥技术运营副总经理21:05-21:10Q&A董欣博士 逻晟生物嘉宾：逻晟生物 董事长德国慕尼黑大学生物化学博士，中国科技大学硕士，四川大学学士；匹兹堡大学癌症中心、霍华德·休斯医学研究所博士后；加州大学洛杉矶分校（UCLA）助理研究教授，LIAI 高级科学家。曾担任PaxVax高级科学家，负责病毒载体疫苗评价，对外合作，IND申报材料，与FDA沟通等；加入Biogen的孵化器中心BI3之一Neostasis后，带领其团队全面负责新药研发，领导靶点验证、候选抗体筛选、体外/体内测试、抗体人源化及稳定细胞株开发。曾于中美冠科CrownBio担任高级总监，领导多个一体化抗体药物的成功开发。担任南京和苏州银河生物CSO及研发副总，组建研发团队及实验室搭建，主导人源化小鼠平台的合作开发及合作转让，曾在中美两国参与创业，包括PersImmune，南京驯鹿医疗等。朱一翔博士 康日百奥嘉宾：康日百奥 技术运营副总经理毕业于华东理工大学生物反应器工程国家重点实验室，近 10 年生物制药行业经验，在生物药 CMC 开发，技术转移，生产和项目管理方面经验丰富。在中国主导开发了 20 余个单抗，双抗和融合蛋白产品，其中已有 11 个获得了包括 NMPA，FDA 和 TGA 的临床研究批准。沈旭 康日百奥主持人：康日百奥 项目管理总监10年以上生物医药行业项目管理工作经验。具有生物药物开发的全生命周期的项目管理经验，包括IND申报，临床研究，晚期CMC研究，产品上市及上市后变更等阶段。曾参与4个上市申报项目，作为项目经理负责国内头部生物药企业首个上市项目的项目管理工作。参与和指导20个以上IND项目，包括抗体新药和生物类似物CMC研究，中国、澳大利亚及美国的IND申报。点击原文链接「报名」进入此活动直播间！